Antisoma and Heraeus Sign Agreement for Manufacture of AS1410

Cancer drug developer Antisoma announces that it has signed an agreement with German specialist manufacturer Heraeus to provide supplies of AS1410 for clinical trials. Development of the drug, which is Antisoma's lead telomere targeting agent (TTA), has progressed rapidly, and the company now expects its plan to start clinical trials next year will be achieved during the first half of 2006. TTAs attack cancer cells by binding directly to telomeres, which are regions at the ends of chromosomes.

()a href="http://www.primezone.com/newsroom/?d=79273" target="_blank">PrimeZone